A61K 40/4251
Kinases
Official title: {Kinases, e.g. Raf or Src}
A61K40/4251 (Kinases) appears on 46 US grants and 119 published applications in this corpus.
Search patents in A61K- Granted patents
- 46
- Published applications
- 119
- Assignees
- 78
- Inventors
- 259
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 1 |
| 2010 | 0 | 1 |
| 2011 | 0 | 3 |
| 2012 | 1 | 1 |
| 2013 | 2 | 1 |
| 2014 | 1 | 5 |
| 2015 | 3 | 2 |
| 2016 | 1 | 2 |
| 2017 | 2 | 2 |
| 2018 | 1 | 3 |
| 2019 | 2 | 7 |
| 2020 | 1 | 5 |
| 2021 | 4 | 11 |
| 2022 | 3 | 9 |
| 2023 | 2 | 17 |
| 2024 | 12 | 21 |
| 2025 | 7 | 13 |
| 2026 | 4 | 13 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- CALR and JAK2 T-cell receptors2 Jun 2026US 12,643,931 B2Janssen Biotech, Inc.
- Compositions and methods of muscle specific kinase chimeric autoantibody receptor cells26 May 2026US 12,637,501 B2The Trustees of the University of Pennsylvania
- Chimeric receptors and methods of use thereof28 Apr 2026US 12,611,458 B2Senti Biosciences, Inc.
- Pretreatment drug for T cell infusion therapy for immune-checkpoint inhibitor-resistant tumor10 Mar 2026US 12,569,562 B2Kyoto University
- T cell receptors targeting PIK3CA mutations and uses thereof9 Dec 2025US 12,492,237 B2Memorial Sloan Kettering Cancer Center
- Engineered immune cells for treating cancer in combination with il-2/il-15 receptor beta-gamma agonists24 Sep 2026US 2026/0284145 A1Sotio Biotech Inc.
- Hla-a3-restricted t cell receptors against braf with v600e mutation20 Aug 2026US 2026/0242513 A1The United States of America, as represented by the Secretary, Department of Health and Human Servic
- Chimeric receptors and methods of use thereof13 Aug 2026US 2026/0232803 A1Senti Biosciences, Inc.
- Calr and jak2 t-cell receptors2 Jul 2026US 2026/0184761 A1Janssen Biotech, Inc.
- Engineered t cells having altered pyruvate metabolism, methods for their production and use in therapy, e.g., for treatment of cancer or infection25 Jun 2026US 2026/0174850 A1Trustees of Dartmouth College
Most cited
By later US patents
- Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods23US 8,486,693 B2Bellicum Pharmaceuticals, Inc. · 2013
- Transgenic macrophages, chimeric antigen receptors, and associated methods21US 10,415,017 B2Thunder Biotech Inc. · 2019
- Cancer stem cell antigen vaccines and methods20US 8,129,184 B2Cedars-Sinai Medical Center · 2012
- Anti-ROR1 antibodies and uses thereof12US 10,968,275 B2Fred Hutchinson Cancer Research Center · 2021
- Inhibition of dendritic cell-driven regulatory T cell activation and potentiation of tumor antigen-specific T cell responses by interleukin-15 and MAP kinase inhibitor9US 8,546,137 B2Board of Trustees of the University of Arkansas · 2013